Differential Expression Profiling of Industrially Relevant CHO Cell Phenotypes Using a Proprietary CHO-Specific Microarray and Proteomics Technology Platforms

We have previously reported on the development and use of a proprietary CHO-specific microarray and proteomics technology platforms to interrogate large and diverse sets of CHO cell samples, which embodied several industrially relevant phenotypes. In a collaboration between Wyeth BioPharma and NICB/Dublin City University, we have completed the analysis of 375 individual samples representing 29 different recombinant CHO cell lines expressing monoclonal antibody, receptor-Fc fusion molecules, coagulation factors or growth factors. In this paper, we will present key learnings and insights that we have made upon analysis of the large dataset generated by the collaboration. Of note is that, despite sometimes large differences in observed phenotypes, the changes that we measured in the genomics and proteomics experiments were relatively subtle. Lastly, functional validation is important to confirming the relevance of any particular target. The development of a robust, comprehensive, and high-throughput validation workflow will be discussed.